Inhibition of the MAPK signalling pathway through agents such as dabrafenib, vemurafenib, binimetinib, encorafernib, trametinib, selumetinib, and cobimetinib, which bind to signal cascade kinases BRAF and MEK, has become a crucial treatment strategy for patients with BRAF-mutant melanoma [9,10,11,12]. Here, BRAF is linked to melanoma.